18 January 2023 - - Dr. Anne Borgman has been appointed to US-based clinical stage biotechnology company NiKang Therapeutics Inc's board of directors, the company said.

Dr. Borgman joins the NiKang board of directors with over 20 years of experience in clinical development of oncology and hematology therapeutics.

Dr. Borgman has led teams to the successful approval of several oncology drugs including recombinant asparaginase using the intensive Real Time Oncology Review process while she was the vice president and Global Therapeutic Area Lead, Hematology-Oncology at Jazz Pharmaceuticals, and cabozantinib for the treatment of renal cell carcinoma, hepatocellular carcinoma and thyroid cancer while she served as the vice president of Clinical Research and Development at Exelixis.

As the Chief Medical officer at Hana Biosciences, Dr. Borgman led the filing for an accelerated approval for liposomal vincristine in adult relapsed acute lymphoblastic lymphoma.

Dr. Borgman currently serves on the board of directors at Curis, Inc. and NextCure, Inc. She has previously held position of Consulting Associate Professor at Stanford University in the Department of Pediatrics in the School of Medicine.

Prior to Stanford, Dr. Borgman held positions of Consulting Attending Physician at University of Chicago Comer Children's Hospital in the Department of Pediatric Hematology/Oncology and Stem Cell Transplant and Global Project Head early in her career at Abbott Laboratories.

Dr. Borgman earned her M.D. from Loyola University of Chicago's Stritch School of Medicine, completed a residency in pediatrics at Texas Children's Hospital, Baylor College of Medicine and a fellowship in pediatric hematology-oncology and stem cell transplant at UCLA David Geffen School of Medicine.

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.